Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (1409)	4/7/2003 9:43:38 AM
From: tuck	Read Replies (1) \| Respond to of 1784

Oddly, this does not mention Xenogen's in vivo imaging expertise: >>WILMINGTON, Mass.--(BUSINESS WIRE)--April 7, 2003-- Charles River Laboratories International, Inc. (NYSE:CRL - News), a leading provider of pre-clinical research products and services to biopharmaceutical and biotechnology companies, and Xenogen Biosciences, a wholly-owned subsidiary of Xenogen Corporation, today announced the formation of a marketing collaboration that seeks to speed the availability of genetically-modified research models to the pharmaceutical, biotechnology and academic research scientist. In this two-year strategic collaboration, Charles River will market Xenogen Biosciences' genomic services to the clients of its Transgenic Services business. Xenogen Biosciences, located in Cranbury, New Jersey, holds intellectual property rights to multiple processes for the development of knock-out, knock-in and transgenic models, including the process of pronuclear microinjection, one of the most widespread techniques used to genetically engineer new research models. "We have long known the importance of offering a services portfolio that includes the genomic manipulation of research models to make them more predictive of the human," said Bill Barbo, Executive Director, Charles River Transgenic Services. "With this collaboration, we will be able to market Xenogen's genomic technology as a seamless addition to our services, enabling us to further assist our clients in the more efficient pursuit of their research goals." "We are pleased with the opportunity to offer our broad range of services in conjunction with Charles River, the acknowledged leader in our market," said Pamela Reilly Contag, Ph.D., President of Xenogen Corporation. "The combination of Xenogen Biosciences' genomic technology and Charles River's market share leadership in the Research Model and Transgenic Services arena makes this collaboration a win-win for the pharmaceutical, biotech and research communities." Xenogen Biosciences offers a range of genomic services that can create a gene-specific research model. Charles River is recognized as the market leader in model development and breeding services associated with providing a continuing supply of genetically specific and virally clean research models for clients around the world. The strategic marketing agreement leverages the strengths of both companies to provide customers with more comprehensive outsourcing services to accelerate their drug discovery process. << snip Cheers, Tuck